Key Drivers
- High margins
- Strong FCF
- Liquidity risk
AIAI Summary
Treat Medpace as a high-quality cash-flow compounder whose equity upside is now conditional—key positive is durable FCF and a large backlog, but the pivotal risk/opportunity is whether passthrough mix normalizes and book-to-bill stays >1.15 with low cancellations (and a clean resolution of the securities inquiry); if not, premium multiples leave material downside. Investors should position for stable cash returns while requiring clear multi-quarter evidence of passthrough decline and consistent backlog conversion before re-rating the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong FCF
- •Liquidity risk
MEDP delivers strong profitability and cash generation (high margins, $682M FCF) but faces liquidity and leverage risks from negative working capital, large deferred revenue/intangibles and elevated valuation.
Price Behavior
Key Price Behavior Insights:
- •Neutral momentum
- •Defined S/R
- •Elevated volatility
Over the last month MEDP has traded essentially flat in a narrow range with modestly negative momentum—about 1% below the ~$457 last-month SMA—holding support near $438 and facing resistance around $477–$479 amid elevated intra-period volatility (~9–10% range).
Elevated intra-period volatility with a ~9–10% range from the low on 2026-02-25 to the high on 2026-03-09
Sentiment & News
Key News Insights:
- •Regulatory probe
- •Mixed ratings
- •Active institutions
Medpace faces a shareholder probe and muted analyst sentiment amid mixed institutional buying and trimming, yet the stock has posted modest recent gains.
The investigation and cautious broker stance raise near-term risk, but continued institutional interest and recent price resilience may support medium-term stability
Similar Companies in Healthcare
Other companies in the same sector with AI ratings